Filing Details

Accession Number:
0001104659-24-037977
Form Type:
4/A
Zero Holdings:
No
Publication Time:
2024-03-22 17:51:44
Reporting Period:
2024-03-13
Accepted Time:
2024-03-22 17:51:44
Original Submission Date:
2024-03-14
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
1711933 Akoya Biosciences Inc. AKYA Laboratory Analytical Instruments (3826) 475586242
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1857447 Brian Mckelligon 100 Campus Drive, 6Th Floor
Marlborough MA 01752
President And Ceo Yes Yes No No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock Acquisiton 2024-03-13 7,500 $0.30 239,368 No 4 M Direct
Common Stock Disposition 2024-03-13 7,500 $4.94 231,868 No 4 S Direct
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 M Direct
No 4 S Direct
Reported Derivative Transactions
Sec. Name Sec. Type Acquisiton - Disposition Date Amount Price Amount - 2 Price - 2
Common Stock Employee Stock Option (Right to Buy) Disposition 2024-03-13 7,500 $0.00 7,500 $0.30
Remaning Holdings Exercise Date Expiration Date Equity Swap Involved Transaction Form Type Transaction Code Nature of Ownership
298,129 2027-11-09 No 4 M Direct
Footnotes
  1. The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by Brian M. McKelligon dated August 16, 2023.
  2. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $4.81 to $5.08, inclusive. The reporting person undertakes to provide to Akoya Biosciences, Inc., any security holder of Akoya Biosciences, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth.
  3. The option, representing a right to purchase a total of 353,129 shares, became exercisable as follows: one-fourth of the shares vested on July 14, 2018 with the remaining shares vesting in 36 equal monthly installments beginning on August 14, 2018, subject to reporting person's continuous employment.